NovaBay Issues Statement Regarding Market Activity
29. Februar 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals Provides Business Update and 2012 Outlook
09. Februar 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Progress Across Four Business Units
Conference Call and Webcast Today at 1:00 P.M. (ET) / 10:00 A.M. (PT)
Dial-In Numbers
1-866-761-0748 (USA) or 1-617-614-2706 (International)
Participant...
NovaBay Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
08. Februar 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook
07. Februar 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 7, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422
23. Januar 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Selects Top Contract Research Organizations to Manage Clinical Trial
Study to Enroll Patients With Confirmed Adenoviral Conjunctivitis in India, Brazil and U.S.
EMERYVILLE, Calif., Jan. 23,...
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
09. Januar 2012 09:06 ET
|
NovaBay Pharmaceuticals, Inc.
NovaBay to Receive Up to $1.3M in Upfront and Milestone Payments
Seeks Strategic Partners for Additional Global Territories
EMERYVILLE, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- NovaBay®...
NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program
30. November 2011 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Part B of Study With More Potent Formulation Currently Underway
EMERYVILLE, Calif., Nov. 30, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage...
NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future
14. November 2011 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
NVC-422 Called "Effective Alternative to Known Antimicrobial Compounds"
EMERYVILLE, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- A monograph on NovaBay's lead Aganocide® NVC-422 was recently...
NovaBay Pharmaceuticals Reports Third Quarter Financial Results
07. November 2011 08:30 ET
|
NovaBay Pharmaceuticals, Inc.
Programs in Dermatology, Urology, Ophthalmology and Wound Care Advancing
EMERYVILLE, Calif., Nov. 7, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage...
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
14. Oktober 2011 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
NeutroPhase is a FDA 510(k) cleared advanced wound care product addressing the un-met medical needs of the six-million-patient USA chronic wound care market
EMERYVILLE, Calif., Oct. 14, 2011...